Amlodipine Contraindications and Adverse Effects
Contraindications
The only absolute contraindication to amlodipine is known hypersensitivity or allergy to amlodipine itself 1. This is straightforward and clearly defined in the FDA labeling.
Additional Clinical Cautions (Not Absolute Contraindications)
While not absolute contraindications, avoid amlodipine in patients with heart failure with reduced ejection fraction (HFrEF) unless other agents are inadequate 2. The 2017 ACC/AHA guidelines specifically note that amlodipine or felodipine may be used if required in HFrEF, but they are not first-line agents 2. The 2015 AHA/ACC scientific statement confirms that amlodipine appeared safe in severe systolic heart failure in the PRAISE trial, distinguishing it from non-dihydropyridine CCBs (diltiazem, verapamil) which should be strictly avoided in HFrEF due to negative inotropic effects 3.
Key distinction: Non-dihydropyridine CCBs (diltiazem, verapamil) are contraindicated in HFrEF, while amlodipine (a dihydropyridine) may be cautiously used if needed 3.
Adverse Effects
Most Common Adverse Effects
Peripheral edema is the most frequent adverse effect of amlodipine, occurring in a dose-dependent manner: 1.8% at 2.5 mg, 3.0% at 5 mg, and 10.8% at 10 mg (compared to 0.6% with placebo) 1. This edema is notably more common in women (14.6%) than men (5.6%) 1.
Other common dose-related adverse effects include:
- Dizziness: 1.1-3.4% (dose-dependent) 1
- Flushing: 0.7-2.6% (dose-dependent), more common in women (4.5% vs 1.5% in men) 1
- Palpitations: 0.7-4.5% (dose-dependent), more common in women (3.3% vs 1.4% in men) 1
Other Significant Adverse Effects (>1% incidence)
Rare But Important Adverse Effects (<1% but >0.1%)
Cardiovascular: Arrhythmias (including ventricular tachycardia and atrial fibrillation), bradycardia, syncope, tachycardia 1
Dermatologic: Angioedema, erythema multiforme, pruritus, rash 1. Recent case reports describe interstitial granulomatous drug reaction (IGDR), which can develop weeks to months after starting amlodipine and persist after discontinuation 4.
Gastrointestinal: Gingival hyperplasia, pancreatitis 1
Hematologic: Leukopenia, purpura, thrombocytopenia 1
Metabolic: Hyperglycemia 1. A 2026 pharmacovigilance analysis identified hyperglycemia as a potential safety signal compared to some other antihypertensives, though reports of type 2 diabetes were less frequent 5.
Critical Safety Considerations
Paradoxical angina worsening: Rarely, when first starting amlodipine or increasing the dose, patients may experience worsening angina or myocardial infarction—this requires immediate medical attention 1.
Overdose toxicity: Amlodipine overdose can cause hypotension, bradydysrhythmia, cardiac arrest, and in rare cases, non-cardiogenic pulmonary edema 6.
Clinical Advantages Related to Adverse Effects
The gradual onset and long half-life (35-50 hours) of amlodipine result in fewer vasodilatory side effects (headache, flushing, dizziness) compared to other dihydropyridines like nitrendipine 7. Amlodipine does not adversely affect serum glucose, lipid levels, or cardiac conduction 1, 8.
Discontinuation rates due to adverse effects are low: only 1.5% in clinical trials, not significantly different from placebo 1.